Last 844.15 INR
Change Today -3.10 / -0.37%
Volume 7.1K
ASTR On Other Exchanges
Symbol
Exchange
Natl India
As of 6:05 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca pharma india ltd (ASTR) Snapshot

Open
845.00
Previous Close
847.25
Day High
854.70
Day Low
838.10
52 Week High
03/4/14 - 1,286
52 Week Low
01/30/14 - 725.20
Market Cap
21.1B
Average Volume 10 Days
13.1K
EPS TTM
-0.20
Shares Outstanding
25.0M
EX-Date
07/9/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ASTRAZENECA PHARMA INDIA LTD (ASTR)

Related News

No related news articles were found.

astrazeneca pharma india ltd (ASTR) Related Businessweek News

No Related Businessweek News Found

astrazeneca pharma india ltd (ASTR) Details

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. The company primarily offers products in the areas of cardiovascular and metabolic diseases; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal diseases. It also provides clinical trial services on pharmaceutical products. The company was founded in 1979 and is headquartered in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

1,559 Employees
Last Reported Date: 09/11/14
Founded in 1979

astrazeneca pharma india ltd (ASTR) Top Compensated Officers

Managing Director, Director, Member of Share ...
Total Annual Compensation: 12.3M
Whole-Time Director and Member of Share Trans...
Total Annual Compensation: 8.7M
Compensation as of Fiscal Year 2014.

astrazeneca pharma india ltd (ASTR) Key Developments

AstraZeneca Pharma India Ltd Appoints Rebekah Martin as an Additional Director

AstraZeneca Pharma India Ltd. announced that the board of directors of the company at its meeting held on November 03, 2014, has appointed Ms. Rebekah Martin as an Additional Director of the company, effective November 03, 2014.

Astrazeneca Pharma India Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

AstraZeneca Pharma India Limited reported unaudited standalone earnings results for the second quarter and six months ended September 30, 2014. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 1,145.502 million compared to INR 1,155.824 million a year ago. Loss from operations before other income finance costs and exceptional items was INR 295.668 million compared to INR 40.572 million a year ago. Loss from ordinary activities before tax was INR 279.60 million compared to INR 7.175 million a year ago. Net loss for the period was INR 279.60 million compared to INR 12.264 million a year ago. Basic and diluted loss per share was INR 11.18 compared to INR 0.49 a year ago. For the six months, the company reported net sales of INR 2,401.228 million compared to INR 2,407.196 million a year ago. Loss from operations before other income finance costs and exceptional items was INR 489.60 million compared to INR 51.624 million a year ago. Profit from ordinary activities before tax was INR 455.602 million compared to loss from ordinary activities before tax of INR 10.509 million a year ago. Net loss for the period was INR 455.602 million compared to profit for the period of INR 5.420 million a year ago. Basic and diluted loss per share was INR 18.22 compared to basic and diluted loss per share of INR 0.22 a year ago.

AstraZeneca Pharma India Limited to Report Q2, 2015 Results on Nov 03, 2014

AstraZeneca Pharma India Limited announced that they will report Q2, 2015 results on Nov 03, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ASTR:IN 844.15 INR 0.00

ASTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ASTR.
View Industry Companies
 

Industry Analysis

ASTR

Industry Average

Valuation ASTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 16.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PHARMA INDIA LTD, please visit www.astrazenecaindia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.